Sanofi/Genzyme Saga: War Before Peace?
Executive Summary
Unless a white knight bidder emerges to thwart Sanofi-Aventis' attempt to acquire Genzyme, and soon, the Cambridge-Mass.-based biotech's best negotiating tactic may be stalling.
You may also be interested in...
Sanofi Holds Its Ground On Genzyme Bid
CEO Viehbacher defended Sanofi's $69-per-share hostile bid for Genzyme while reporting third quarter financial results -- even as the French Pharma took a hit from generic Lovenox.
Sanofi Holds Its Ground On Genzyme Bid
CEO Viehbacher defended Sanofi's $69-per-share hostile bid for Genzyme while reporting third quarter financial results -- even as the French Pharma took a hit from generic Lovenox.
Genzyme To Sanofi: How About $89-Per-Share? Answer: "Very Unrealistic"
Genzyme is out to convince investors that Sanofi's hostile bid significantly undervalues the biotech, laying out the reasons why at a meeting in New York Oct. 23.